Accéder au contenu
Merck

50394-U

Ascentis® Express 90Å C8 (5 μm) HPLC Columns

L × I.D. 25 cm × 4.6 mm, HPLC Column

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
25 cm × 4.6 mm
Particle size:
5 μm
Matrix active group:
C8 (octyl) phase
Pore size:
90 Å pore size
Matrix:
Fused-Core particle platform, superficially porous particle
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider


Nom du produit

Ascentis® Express C8, 5 μm HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm

material

stainless steel column

Quality Level

agency

suitable for USP L7

product line

Ascentis®

feature

endcapped

manufacturer/tradename

Ascentis®

packaging

1 ea of

parameter

60 °C temp. range, 600 bar max. pressure (9000 psi)

technique(s)

HPLC: suitable, LC/MS: suitable

L × I.D.

25 cm × 4.6 mm

surface area

90 m2/g

impurities

<5 ppm metals

matrix

Fused-Core particle platform, superficially porous particle

matrix active group

C8 (octyl) phase

particle size

5 μm

pore size

90 Å pore size

operating pH

2-9

application(s)

food and beverages

separation technique

reversed phase

General description

Ascentis® Express 5 μm C8 is a high-speed, high-performance liquid chromatography column based on the highly efficient Fused-Core® particle design. The Fused-Core particle provides a thin porous shell of high-purity silica surrounding a solid silica core. This particle design exhibits very high column efficiency due to the shallow diffusion paths in the 0.6-micron thick porous shell and the highly uniform overall particle size of 5-microns. The densely bonded, extensively endcapped dimethyloctyl stationary phase of Ascentis Express 5 μm C8 provides a stable, reversed-phase packing that can be used for basic, acidic, or neutral compounds.

Other Notes

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
Fused-Core is a registered trademark of Advanced Materials Technology, Inc.


Still not finding the right product?

Explore all of our products under


Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents


Contenu apparenté

Ascentis® Express 5 μm Column Care & Use Sheet (C8, Phenyl-hexyl)


Sreenivasa Rao Chitturi et al.
Journal of pharmaceutical and biomedical analysis, 55(1), 31-47 (2011-02-15)
This paper proposes a simple and selective RP-HPLC method for the determination of process impurities and degradation products (degradants) of atazanavir sulfate (ATV) drug substance. Chromatographic separation was achieved on Ascentis(®) Express C8, (150mm×4.6mm, 2.7μm) column thermostated at 30°C under
Ugandar Reddy Inugala et al.
Journal of chromatographic science, 51(5), 453-459 (2012-10-13)
This paper describes the development of a rapid, novel, stability-indicating gradient reversed-phase high-performance liquid chromatographic method and associated system suitability parameters for the analysis of naproxcinod in the presence of its related substances and degradents using a quality-by-design approach. All
Luigi Silvestro et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 878(30), 3134-3142 (2010-10-20)
Quantitative methods using LC-MS/MS allow achievement of adequate sensitivity for pharmacokinetic studies with clopidogrel; three such methods, with LLOQs as low as 5 pg/mL, were developed and fully validated according to the well established FDA 2001 guidelines. The chromatographic separations